RxDoctor Payments Data

Benjamin Chen, MD

Obstetrics & Gynecology · Roseville, MINPI 1245230457

Payments from drug & device makers

$5,285in general payments, 2019–2025

Across 243 payments — averaging $21.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$635
  • Sumitomo Pharma America, Inc.$490
  • Astellas Pharma US Inc$469
  • Intuitive Surgical$434
  • Aspira Women's Health Inc$303
  • Therapeuticsmd, Inc.$254
  • plus $3K from 32 others

What the payments were for

  • Travel & lodging$4348%
  • Food & beverage$4,75190%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,285 in reported general payments places this provider in the 90th percentile of 1,474 obstetrics & gynecology providers in Michigan.

See all obstetrics & gynecology providers in Michigan

Medicare billing

Part B allowed, 2024
$101,257
Medicare patients
218
Services billed
1,392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VeozahFezolinetant11$7,028
Estradiol89$6,499
ValacyclovirValacyclovir Hcl51$2,151
Estradiol (Twice Weekly)Estradiol22$1,884
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet50$1,444
Clobetasol Propionate43$1,157
Raloxifene Hcl25$1,138
Ibandronate Sodium25$1,015
Norethindrone Acetate36$378
Oxybutynin Chloride ErOxybutynin Chloride19$350
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst32$326
Metronidazole15$301
Acyclovir14$299
Nystatin15$249
Venlafaxine Hcl ErVenlafaxine Hcl12$196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncVeozah$469$7,02811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,474 obstetrics & gynecology providers in Michigan.

Other obstetrics & gynecology in Roseville

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →